{
    "ticker": "HRMY",
    "name": "Harmony Biosciences Holdings, Inc.",
    "description": "Harmony Biosciences Holdings, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients living with rare neurological diseases. Founded in 2017, Harmony focuses on addressing unmet medical needs through its proprietary product pipeline, which includes treatments for conditions such as narcolepsy and other sleep disorders. The company's lead product, Wakix (pitolisant), has gained recognition for its efficacy in treating excessive daytime sleepiness associated with narcolepsy, and it has been approved in multiple markets, including the United States and Europe. Harmony's commitment to research and development is driven by a patient-centric approach, aiming to improve the quality of life for individuals affected by complex neurological conditions. The company also emphasizes collaboration with healthcare professionals and advocacy groups to ensure that the voices of patients are heard and considered in the development of new therapies. Harmony Biosciences is poised for growth as it expands its portfolio and continues to explore additional therapeutic areas within neurology. The company aims to lead in the biopharmaceutical sector by delivering innovative solutions and contributing to the advancement of science and medicine.",
    "industry": [
        "Biopharmaceuticals",
        "Neurology"
    ],
    "headquarters": "Philadelphia, Pennsylvania, USA",
    "founded": "2017",
    "website": "https://www.harmonybiosciences.com",
    "ceo": "John R. McDonough",
    "social_media": {
        "twitter": "https://twitter.com/HarmonyBiosci",
        "linkedin": "https://www.linkedin.com/company/harmony-biosciences/"
    },
    "investor_relations": "https://investors.harmonybiosciences.com",
    "key_executives": [
        {
            "name": "John R. McDonough",
            "position": "CEO"
        },
        {
            "name": "Diane M. M. H. Becker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Medications",
            "products": [
                "Wakix (pitolisant)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Harmony Biosciences Holdings, Inc. | Innovative Neurology Therapies",
        "meta_description": "Explore Harmony Biosciences, a biopharmaceutical leader dedicated to developing innovative therapies for rare neurological diseases. Learn about their mission and products.",
        "keywords": [
            "Harmony Biosciences",
            "Neurology",
            "Wakix",
            "Narcolepsy",
            "Biopharmaceuticals",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Harmony Biosciences focus on?",
            "answer": "Harmony Biosciences focuses on developing innovative therapies for rare neurological diseases."
        },
        {
            "question": "What is Harmony's lead product?",
            "answer": "Harmony's lead product is Wakix (pitolisant), used to treat narcolepsy."
        },
        {
            "question": "When was Harmony Biosciences founded?",
            "answer": "Harmony Biosciences was founded in 2017."
        },
        {
            "question": "Where is Harmony Biosciences headquartered?",
            "answer": "Harmony Biosciences is headquartered in Philadelphia, Pennsylvania, USA."
        },
        {
            "question": "Who is the CEO of Harmony Biosciences?",
            "answer": "The CEO of Harmony Biosciences is John R. McDonough."
        }
    ],
    "competitors": [
        "AVDL",
        "VYGR",
        "SAGE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}